Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...

Sam­sung Bi­o­log­ics is split­ting apart its con­tract man­u­fac­tur­ing and biosim­i­lar de­vel­op­ment ac­tiv­i­ties in a bid to en­hance their com­pet­i­tive­ness.

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...

Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position ...

Biocon Biologics, subsidiary of Biocon, announced today that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection [YD], a biosimilar to the reference ...

Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

In the published article, the reference for (5) was incorrectly written as “Georgalas, L, Tservakis, I, Kiskira, EE, Petrou, P, Papaconstantinou, D, and Kanakis, M. Efficacy and safety of intravitreal ...

Fresenius Kabi also makes biosimilars, the generic forms of expensive biologic drugs such as Humira and Stelara. The United States is typically the last developed country where biosimilars appear on ...

AEON Biopharma, Inc. announced plans to advance its biosimilar product ABP-450, leveraging the 351(k) regulatory pathway with the goal of obtaining FDA approval for all indications currently ...

Aurobindo Pharma subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation for Zefylti, its filgrastim biosimilar version, from Medicines and Healthcare products Regulatory Agency ...

Understanding what sets IL-23 inhibitors apart in the IBD management paradigm may hold clues to where each biologic and biosimilar product will fall in terms of uptake and patient satisfaction.

“So far, most biosimilars (particularly TNF inhibitors) have performed as well as the original biologics,” Dr. Cron says. “The general risks should be very similar to the parent biologic.” However, in ...